Condition

Heart Failure and Reduced Ejection Fraction

ClinicalTrials.gov condition label

Explore related research

Search across original and mapped records

Search results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 18 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials18
Recruiting7
Common interventions25
Lead sponsors shown15
Advertisement

Clinical trials

18 shown
Infusing Needed Iron to Target Insufficiency in Adults Treated for Evidence of Heart FailureNCT07467668 · 2026-04-20
RECRUITING
Selenium Intervention Registry Randomized Trial in Heart FailureNCT07543562 · 2026-04-01
RECRUITING
Propensity-Matched Study of Cardiac Contractility Modulation Therapy in Heart FailureNCT07209098 · 2025-11-18
RECRUITING
Comparing Three Types of Specialist Pacemakers to Improve Heart Function and Reduce Rhythm Problems in Heart FailureNCT07430553 · 2025-11-12
RECRUITING
Biomarkers for Left Ventricular Reverse Remodeling in Heart Failure (REVERT-HF)NCT07701876 · 2025-11-01
RECRUITING
Developing a Digital Aid to Improve ICD DecisionsNCT07084142 · 2025-08-01
RECRUITING
Secondary Mitral Regurgitation Treatment With MitraClip and Assessment by Cardiac Magnetic ResonanceNCT07131631 · 2022-03-03
RECRUITING
RELIEVE-HFrEF TRIAL: REducing Lung congestIon Symptoms Using the v-wavE Shunt in adVancEd Heart Failure With Reduced EFNCT07696975 · 2026-09-30
NOT_YET_RECRUITING
Wearable Device-Assisted Remote Management to Improve Prognosis in Patients With Acute Heart Failure Complicated by Atrial Fibrillation: WARM-HF Trial (Stage 2)NCT07687862 · 2026-09-01
NOT_YET_RECRUITING
Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With ObesityNCT07738276 · 2026-07-18
NOT_YET_RECRUITING
Comparative Effects of Different Inspiratory Muscle Training Modalities in Patients With Heart Failure.NCT07688863 · 2026-06-17
ENROLLING_BY_INVITATION
Evaluation of Accelerated Bachmann Bundle Area Pacing in Heart Failure With Reduced ejectIon Fraction Who Have electrocarDioGraphic Evidence of Interatrial Block and Indicated for Implantable Cardioverter DefibrillatorNCT07547306 · 2026-05-01
NOT_YET_RECRUITING
Effectiveness and Safety of Uptitration of Guideline Directed MEdical Therapy in Heart Failure With Reduced Ejection Fraction With Limited Kidney Function AssessmentsNCT07275437 · 2026-04-01
NOT_YET_RECRUITING
PRIMA-HF: Predicting Myocardial Recovery in Heart Failure Using Cardiac Imaging HAI-HF: High Dosing vs. Standard Dosing Adenosine During Myocardial Perfusion in Heart FailureNCT07243119 · 2025-12-08
ENROLLING_BY_INVITATION
Cardiac Left Atrial Evaluation and Response in HFrEF With Sacubitril/ValsartanNCT07088471 · 2024-11-01
COMPLETED
The Effect of Ozone Treatment on Coronary Flow Reserve in Patients With Heart Failure Having Reduced Ejection FractionNCT07134972 · 2024-01-14
COMPLETED
Effects of a Transitional Care Program on Depression, Self-Efficacy, and Self-Care in Patients With Heart FailureNCT07660237 · 2023-07-19
COMPLETED
Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection FractionNCT02874794 · 2016-08-17
COMPLETED

Common interventions

Trial status mix

RECRUITING7
NOT_YET_RECRUITING5
COMPLETED4
ENROLLING_BY_INVITATION2

Phase mix

NA10
PHASE32
PHASE42
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.